Tags

Type your tag names separated by a space and hit enter

IgA-antitissue transglutaminase: validation of a commercial assay for diagnosing coeliac disease.
Clin Lab 2002; 48(5-6):241-6CL

Abstract

We have evaluated a commercial assay for serum IgA class antibodies to tissue transglutaminase, the enzyme identified as the major endomysial autoantigen in coeliac disease (CD). Sera were available from 130 adults diagnosed with CD in Southern Derbyshire between 01 01 97 and 31 12 99. Sera from 100 patients without villous atrophy on small intestinal biopsy were controls. The ability of the assay to detect abnormally low total IgA levels was assessed using sera from 18 subjects with IgA deficiency. Sensitivity and specificity of this IgA-anti tissue transglutaminase (tTGA) assay (86.2%, 91.0%) were inferior to endomysial antibody (EMA; 93.8%, 100%). tTGA has significantly higher sensitivity than IgA-antigliadin (76.2%). tTGA was appropriately undetectable (<0.03 U/mL) in 17 of 18 subjects with selective IgA deficiency. The high likelihood ratio (35) for tTGA at levels >9.0 U/mL and methodological advantages over EMA suggest that tTGA could be used as a first line diagnostic test for CD. At tTGA levels of 4-9 U/mL, use of EMA as a second line test would improve specificity.

Authors+Show Affiliations

Division of Public Health Sciences, Nottingham University Medical School, Queen's Medical Centre, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12071574

Citation

West, J, et al. "IgA-antitissue Transglutaminase: Validation of a Commercial Assay for Diagnosing Coeliac Disease." Clinical Laboratory, vol. 48, no. 5-6, 2002, pp. 241-6.
West J, Lloyd CA, Hill PG, et al. IgA-antitissue transglutaminase: validation of a commercial assay for diagnosing coeliac disease. Clin Lab. 2002;48(5-6):241-6.
West, J., Lloyd, C. A., Hill, P. G., & Holmes, G. K. (2002). IgA-antitissue transglutaminase: validation of a commercial assay for diagnosing coeliac disease. Clinical Laboratory, 48(5-6), pp. 241-6.
West J, et al. IgA-antitissue Transglutaminase: Validation of a Commercial Assay for Diagnosing Coeliac Disease. Clin Lab. 2002;48(5-6):241-6. PubMed PMID: 12071574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgA-antitissue transglutaminase: validation of a commercial assay for diagnosing coeliac disease. AU - West,J, AU - Lloyd,C A, AU - Hill,P G, AU - Holmes,G K T, PY - 2002/6/20/pubmed PY - 2003/1/4/medline PY - 2002/6/20/entrez SP - 241 EP - 6 JF - Clinical laboratory JO - Clin. Lab. VL - 48 IS - 5-6 N2 - We have evaluated a commercial assay for serum IgA class antibodies to tissue transglutaminase, the enzyme identified as the major endomysial autoantigen in coeliac disease (CD). Sera were available from 130 adults diagnosed with CD in Southern Derbyshire between 01 01 97 and 31 12 99. Sera from 100 patients without villous atrophy on small intestinal biopsy were controls. The ability of the assay to detect abnormally low total IgA levels was assessed using sera from 18 subjects with IgA deficiency. Sensitivity and specificity of this IgA-anti tissue transglutaminase (tTGA) assay (86.2%, 91.0%) were inferior to endomysial antibody (EMA; 93.8%, 100%). tTGA has significantly higher sensitivity than IgA-antigliadin (76.2%). tTGA was appropriately undetectable (<0.03 U/mL) in 17 of 18 subjects with selective IgA deficiency. The high likelihood ratio (35) for tTGA at levels >9.0 U/mL and methodological advantages over EMA suggest that tTGA could be used as a first line diagnostic test for CD. At tTGA levels of 4-9 U/mL, use of EMA as a second line test would improve specificity. SN - 1433-6510 UR - https://www.unboundmedicine.com/medline/citation/12071574/IgA_antitissue_transglutaminase:_validation_of_a_commercial_assay_for_diagnosing_coeliac_disease_ L2 - https://medlineplus.gov/celiacdisease.html DB - PRIME DP - Unbound Medicine ER -